• Company
  • News
  • Investors
  • Contacts
  • Careers
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Generic peptides
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Cosmetic
  • Individualized Peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Generic peptides
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Cosmetic
  • Individualized Peptides
  • Oligos
  • Home
  • News
  • Ad hoc announcements pursuant to Art. 53 LR
  • PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee

PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee

25 June 2021
Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Christina Del Vecchio as General Counsel and member of the Executive Committee. She will join PolyPeptide on 1 September 2021 and will also serve as the company’s Corporate Secretary.

PolyPeptide CEO Raymond De Vré comments: “We are excited to welcome Christina who already has a deep knowledge and understanding of our company having worked closely with us on our recent IPO on SIX Swiss Exchange. With her extensive international legal and public company experience as well as her pragmatic and commercial mindset, Christina brings the ideal blend of capabilities for this newly created role, aimed at supporting our organization as we develop and grow our global business.”

Christina Del Vecchio joins PolyPeptide from Niederer Kraft Frey AG, a leading Swiss law firm based in Zurich, where she has worked since 2013, becoming counsel in 2018. Prior to joining Niederer Kraft Frey AG, she was an associate at Latham & Watkins LLP in their London office. Over the course of her career, Christina has advised numerous Swiss and international companies on a wide range of commercial and financing transactions, securities laws, governance, compliance and other legal matters.

Christina graduated from Columbia Law School in 2008, where she was recognized as a James Kent Scholar, and summa cum laude from the University of Florida in 2000 with a Bachelor of Arts. Christina, who was born in 1978 and raised in the U.S., is a Swiss and Swedish citizen.

Contact
Michael Stäheli, Head of Investor Relations & Corporate Communications
michael.staeheli@polypeptide.com, +41 41 723 20 34

About PolyPeptide Group
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide’s shares (SIX: PPGN) are listed on the Swiss Stock Exchange. For more information, visit polypeptide.com.

Disclaimer
This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Additional features:

File: PolyPeptide_General_Counsel_EN


End of ad hoc announcement

 

Download PDF

Back to news

Related posts

30 January 2023

CEO of PolyPeptide resigns


Read more
19 December 2022

PolyPeptide signs significant commercial agreement


Read more
2 December 2022

PolyPeptide provides market update


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2021 PolyPeptide Group • Cookie management • Personal data • Sitemap • Confidentiality policy
      By clicking “Accept”, you consent to the use of ALL the cookies on our website . However you may visit Cookie Settings to provide a controlled consent.
      Cookie settingsACCEPT
      Privacy & Cookies Policy

      Privacy Overview

      You can enable or disable your consent for each category of cookie.

      More information on the collection of personal data
      Necessary
      Always Enabled

      The necessary cookies help to make a website usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

      Advertisement

      Marketing cookies are used to track visitors through websites. The goal is to display ads that are relevant and interesting to the individual user and therefore more valuable to third-party publishers and advertisers.

      Analytics

      Statistical cookies help website owners, through the anonymous collection and communication of information, to understand how visitors interact with websites.

      Performance

      Preferences cookies allow a website to retain information that changes the way the site behaves or displays, such as your preferred language or the region in which you are located.

      Save & Accept